Susquehanna International Group, LLP Protalix Bio Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $823 Billion
- Q3 2025
A detailed history of Susquehanna International Group, LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 72,922 shares of PLX stock, worth $135,634. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,922
Previous 298,567
75.58%
Holding current value
$135,634
Previous $441,000
63.27%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PLX
# of Institutions
83Shares Held
10.6MCall Options Held
23.6KPut Options Held
95.4K-
Opaleye Management Inc. Boston, MA2.58MShares$4.8 Million0.96% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.32MShares$2.45 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL902KShares$1.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.52 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$930,0000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $92.5M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...